UK – Evonetix, a Cambridge, UK-based synthetic biology company bringing semiconductor technology to DNA synthesis, raised additional $24M in Series B, extending the total raised in the round to over USD $54M.
The round was led by Foresite Capital, with participation from Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence.The company intends to use the funds for the continued development of its semiconductor chips to commercial scale, and the extension of gene assembly capabilities for its binary assembly technology to deliver accurate, gene-length DNA in a benchtop instrument. Led by CEO Colin McCracken, Evonetix provides a proprietary synthesis process that utilises a novel silicon chip, to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites, or ‘pixels’, and their assembly into highly accurate long DNA on the chip surface through its patented Binary Assembly process. This approach enables the accurate synthesis of thousands of sequences on a single chip to meet the demand for complex libraries and assembly of long DNA in days rather than weeks, accelerating research across the exciting field of synthetic biology.Commenting on the news, Colin McCracken said: “This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionise the accessibility of gene synthesis. Evonetix is in a very exciting phase, having recently opened our early access program. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users.”08/02/2023
